Biocon Limited

Biocon Limited

Biocon Limited has announced the commercial launch of Yesafili™, a biosimilar to Eylea 2 mg, in the United States. The product was approved by the U.S. FDA and granted interchangeable designation, allowing substitution at the pharmacy level. The launch is expected to benefit approximately 20 million adults in the U.S. with age-related macular degeneration and other serious eye conditions.

Biocon Limited

Biocon Limited has received Notice of Compliance (NOC) approval from Health Canada for its subsidiary's Yesintek (ustekinumab) Autoinjector 45 mg/0.05 mL and 90 mg/mL, strengthening its portfolio of immunology products in Canada.

Biocon Limited

Biocon Limited has informed the Exchange about the schedule of a Board meeting and earnings conference call for analysts and investors to discuss the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026.

Biocon Limited

Mylan Inc. has submitted a disclosure under SEBI Takeover Regulations, as per Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Biocon Limited

Biocon Limited has informed the Exchange regarding Change in Director(s) of the company, specifically the completion of tenure of Independent Director Mr. Bobby Kanubhai Parikh.

Biocon Limited

Biocon Limited has informed the Exchange about the publication of the notice of the 48th Annual General Meeting (AGM) and e-voting information in accordance with SEBI regulations.

Biocon Limited

Biocon Limited has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee (insulin glargine) at its insulin manufacturing facility in Malaysia.

Biocon Limited

Biocon Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 06, 2026. The company has also sent the Notice of the 48th AGM and Integrated Annual Report for the Financial Year 2025-26 to its members through electronic mode. The report includes information on the company's performance, governance, and sustainability.

Biocon Limited

Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities during the quarter ended June 30, 2026.

Biocon Limited

Biocon Limited has announced the publication of two clinical studies supporting the effectiveness of Yesafili, a biosimilar to Eylea, in the treatment of diabetic macular edema. The studies were published in the British Journal of Ophthalmology and Expert Opinion on Biological Therapy, and demonstrate comparable safety, efficacy, and immunogenicity profiles between participants who continued treatment with MYL-1701P and those who switched from reference aflibercept.

Biocon Limited

Biocon Limited has informed the Exchange about Copy of Newspaper Publication regarding the 48th Annual General Meeting (AGM) to be held through Video Conferencing or Other Audio Visual Means (VC/OAVM) on August 08, 2026, along with the Integrated Annual Report for the FY 2025-26.

Biocon Limited

Biocon Limited has informed the Exchange regarding allotment of 87,86,362 securities pursuant to Preferential Issue at its meeting held on Jun 29, 2026, as consideration for the acquisition of equity shares of Biocon Biologics Limited.

Biocon Limited

Biocon Limited has informed the Exchange about the acquisition of equity shares of Biocon Biologics Limited and allotment of equity shares of Biocon Limited on preferential basis. The Company has completed the acquisition of 1,15,36,956 equity shares of Biocon Biologics Limited from 127 selling shareholders. The Company has also issued and allotted 87,86,362 equity shares of Biocon Limited to the 127 selling shareholders as consideration for the acquisition. The equity shares allotted shall rank pari-passu with the existing equity shares of the Company.

Biocon Limited

Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Biocon Limited

Biocon Limited announced that its partner, Duopharma Biotech, secured multiple insulin tenders from Malaysia's Ministry of Health, valued at over MYR 225 million. Biocon's Malaysian subsidiary will supply short-acting recombinant human insulin, insulin glargine, and insulin aspart under these contracts, which include a three-year human insulin agreement and two-year agreements for insulin glargine and aspart. This reinforces Biocon's commitment to diabetes care in Malaysia, ensuring continued access to high-quality, cost-effective insulin therapies and strengthening its market presence.

Biocon Limited

Biocon Limited has issued a communication to its shareholders detailing the deduction of Tax at Source (TDS) on the final dividend for the financial year 2025-26. The Board had recommended a final dividend of 10% (Re. 0.50 per equity share) on May 7, 2026, which is subject to shareholder approval at the AGM on August 6, 2026, with July 3, 2026, as the record date. The notice outlines the applicable TDS provisions, varying rates based on shareholder categories and residential status, and requests shareholders to update their PAN and other relevant details to ensure correct tax deduction or exemption.